Neurology

Polypharmacy can contribute to a higher risk of health problems, such as drug interactions and adverse effects.

Sephin1 found to protect oligodendrocytes, axons, and myelin, as well as reduce central nervous system inflammation in multiple sclerosis.

Top news of the day across the health care landscape.

Nonmyeloablative hematopoietic stem cell transplant found to prolong time to multiple sclerosis disease progression compared with disease-modifying therapies.

Ocrelizumab found more effective in reducing the risk of 12-week confirmed disability progression compared with 10 other treatments for relapsing multiple sclerosis.

Trial comparing oral ponesimod versus teriflunomide (Aubagio) in relapsing multiple sclerosis will evaluate annualized relapse rate as well as other disease activity measures.

The rate of palliative care in patients with multiple sclerosis to have died in US hospitals increased from 7.7% to 58.8% over 10 years

Top news of the day across the health care landscape.

How can pharmacists implement nonpharmacologic treatments for patients with dementia?

Transcranial direct current stimulation shows promise in addressing fatigue in patients with multiple sclerosis.

Study results show a genetic risk variant on astrocytes enhances the accessibility of the central nervous system (CNS) to peripheral immune cells, escalating the risk of autoimmune inflammation and multiple sclerosis.

From clinical trials evaluating treatments to studies unearthing new discoveries about the disease's mechanism, these were some of the top newsworthy moments in multiple sclerosis research in 2018.

Top news of the day across the health care landscape.

Experts argue whether a decline in cognitive function should lead to a change in disease-modifying therapy for multiple sclerosis.

Health care providers managing patients with MS should remain cognizant of the link between unhealthy lifestyle behaviors and depression risks.

FDA finds rare but serious risks of stroke and blood vessel wall tears associated with the multiple sclerosis drug alemtuzumab (Lemtrada).

It’s our job to spend as much time as it takes to help patients feel comfortable with the medications they are taking.

The FDA advises health care providers to counsel patients receiving alemtuzumab on symptoms related to stroke and arterial dissection.

FDA officials are warning that stopping treatment with the multiple sclerosis (MS) drug fingolimod (Gilenya) can cause severe worsening.

FDA officials are warning that stopping treatment with the multiple sclerosis (MS) drug fingolimod (Gilenya) can cause severe worsening.

Stopping treatment with fingolimod (Gilenya) can cause the disease to become much worse than before the medicine was started or while it was being taken, FDA officials warned.

New study finds that ocrelizumab (Ocrevus) has the capability to reduce risk of upper extremity disability progression in patients with primary progressive multiple sclerosis (PPMS).

Top news of the day from across the health care landscape.

Study explores the effect of microglia dysregulation on progression of neurodegeneration in disorders such as Alzheimer disease and amyotrophic lateral sclerosis.

Certain environmental conditions, such as salinity and temperature, may incite structural changes in myelin sheaths.